These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15846579)

  • 1. Management of anemia associated with myelodysplastic syndrome.
    Hellström-Lindberg E
    Semin Hematol; 2005 Apr; 42(2 Suppl 1):S10-3. PubMed ID: 15846579
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategies for achieving transfusion independence in myelodysplastic syndromes.
    Thomas ML
    Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
    J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of erythropoietin and other growth factors in transfusion medicine.
    Klingemann HG; Shepherd JD; Eaves CJ; Eaves AC
    Transfus Med Rev; 1991 Jan; 5(1):33-47. PubMed ID: 1802275
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of hematopoietic growth factors in the treatment of neoplastic diseases.
    St Onge J; Jacobson RJ
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):53-63. PubMed ID: 1380737
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anemia in the elderly patient. Is it a myelodysplastic syndrome?].
    MMW Fortschr Med; 2012 Feb; 154(3):26. PubMed ID: 22458163
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anemia due to hematopoietic disorders. 2. Myelodysplastic syndrome].
    Kondo T; Toyama K
    Nihon Naika Gakkai Zasshi; 2006 Oct; 95(10):2036-42. PubMed ID: 17100261
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis.
    Pardanani A; Tefferi A
    Haematologica; 2011 Jan; 96(1):8-10. PubMed ID: 21193428
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.
    Meers S; Breems D; Bries G; Delforge M; Graux C; Ravoet C; Selleslag D; Noens L;
    Acta Clin Belg; 2013; 68(4):253-62. PubMed ID: 24455794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome.
    Med Lett Drugs Ther; 2006 Apr; 48(1232):31-2. PubMed ID: 16625140
    [No Abstract]   [Full Text] [Related]  

  • 11. Restrictive Versus Liberal Transfusion Strategies in Myelodysplastic Syndrome and Beyond.
    Wilde L; Pan J
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):758-762. PubMed ID: 31678078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-Unit Red Cell Transfusions in Stable Anemic Patients.
    Thakkar RN; Podlasek SJ; Rotello LC; Ness PM; Frank SM
    J Hosp Med; 2017 Sep; 12(9):747-749. PubMed ID: 28914281
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of myelodysplastic syndromes.
    Stadler M; Ganser A
    N Engl J Med; 2005 May; 352(20):2134-5; author reply 2134-5. PubMed ID: 15906434
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS; List AF
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
    Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
    Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network.
    Oncology (Williston Park); 1998 Nov; 12(11A):53-80. PubMed ID: 10028503
    [No Abstract]   [Full Text] [Related]  

  • 18. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
    Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
    Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of granulocyte-macrophage colony-stimulating factor in hematopoietic disorders: biology and nature of response.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN
    Semin Hematol; 1992 Oct; 29(4 Suppl 3):4-13. PubMed ID: 1492234
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.